

# Lili Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9228059/publications.pdf>

Version: 2024-02-01

40  
papers

981  
citations

471509

17  
h-index

477307

29  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 1153-1159.	4.6	3
2	Morphine-3-glucuronide upregulates PD-L1 expression & via TLR4 and promotes the immune escape of non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 155-171.	3.0	16
3	Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial-mesenchymal transition and stem-like reprogram. <i>Aging</i> , 2021, 13, 9780-9800.	3.1	11
4	SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. <i>Cell Death and Disease</i> , 2021, 12, 439.	6.3	26
5	Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma. <i>Neoplasia</i> , 2021, 23, 704-717.	5.3	5
6	Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 723172.	4.8	11
7	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	2
8	Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	3
9	Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153093.	2.3	9
10	Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. <i>Oncimmunology</i> , 2020, 9, 1807291.	4.6	63
11	TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 2496-2508.	2.5	49
12	Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 562-570.	4.4	36
13	Factors associated with stigma in community-dwelling stroke survivors in China: A cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116459.	0.6	22
14	The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View. <i>Journal of Cancer</i> , 2019, 10, 721-729.	2.5	21
15	Clinical Significance of Serum Type III Interferons in Patients with Gastric Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 155-163.	1.2	5
16	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. <i>Cell Death and Disease</i> , 2019, 10, 475.	6.3	16
17	CIAPIN1 Targeted NHE1 and ERK1/2 to Suppress NSCLC Cells' Metastasis and Predicted Good Prognosis in NSCLC Patients Receiving Pulmonectomy. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-15.	4.0	8
18	Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 109.	3.0	15

#	ARTICLE	IF	CITATIONS
19	A new perspective: Exploring future therapeutic strategies for cancer by understanding the dual role of B lymphocytes in tumor immunity. <i>International Journal of Cancer</i> , 2019, 144, 2909-2917.	5.1	24
20	Dysfunction of immune system in the development of large granular lymphocyte leukemia. <i>Hematology</i> , 2019, 24, 139-147.	1.5	21
21	A novel MDSC-induced PD-1 <sup>hi</sup> PD-L1 <sup>+</sup> B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. <i>Oncolmmunology</i> , 2018, 7, e1413520.	4.6	61
22	Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma. <i>Clinical Epigenetics</i> , 2018, 10, 129.	4.1	21
23	The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications (Review). <i>Oncology Letters</i> , 2018, 15, 6799-6805.	1.8	51
24	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. <i>Frontiers in Immunology</i> , 2017, 8, 404.	4.8	73
25	Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line. <i>Journal of Cancer</i> , 2017, 8, 3287-3295.	2.5	16
26	Shorter telomere length of T-cells in peripheral blood of patients with lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 2675.	2.0	12
27	MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells. <i>Oncotarget</i> , 2016, 7, 71904-71914.	1.8	7
28	Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes. <i>Oncotarget</i> , 2016, 7, 27479-27488.	1.8	2
29	Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 40106-40114.	1.8	31
30	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. <i>Oncotarget</i> , 2016, 7, 43604-43615.	1.8	45
31	The inflammatory microenvironment in MDS. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1959-1966.	5.4	56
32	Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 830-835.	0.8	17
33	Telomeres and telomerase in T cells of tumor immunity. <i>Cellular Immunology</i> , 2014, 289, 63-69.	3.0	21
34	Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 65-73.	4.2	85
35	Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor <sup>hi</sup> Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia. <i>Journal of Immunology</i> , 2013, 191, 3578-3593.	0.8	18
36	Epigenetic regulation of <i>DACH1</i> , a novel Wnt signaling component in colorectal cancer. <i>Epigenetics</i> , 2013, 8, 1373-1383.	2.7	79

#	ARTICLE	IF	CITATIONS
37	hTERT deficiency in naïve T cells affects lymphocyte homeostasis in myelodysplastic syndrome patients. <i>OncotImmunology</i> , 2013, 2, e26329.	4.6	4
38	Recombinant bovine pancreatic trypsin inhibitor protects the liver from carbon tetrachloride-induced acute injury in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 332-338.	2.4	4
39	Expression and purification of recombinant human interleukin-18 protein using a yeast expression system. <i>Protein Expression and Purification</i> , 2008, 62, 44-48.	1.3	5
40	Expression and Purification of Natural N-Terminal Recombinant Bovine Pancreatic Trypsin Inhibitor from <i>Pichia pastoris</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1680-1685.	1.4	7